- Hillstream BioPharma ( NASDAQ: HILS ) is trading ~8.2% higher premarket after signing an agreement with Applied Biomedical Science Institute to license technology against drug resistant cancers including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer .
- The Applied Biomedical Science Institute has technology to target unique functional epitopes of the cancer targets HER2 and HER3.
- ABSI had granted Hillstream, certain of its technology which if converted to an exclusive license agreement, will allow Hillstream to develop HER2 and HER3 antibodies .
For further details see:
Hillstream rises 8% on agreement to license technology for HER2 and HER3 antibodies